日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

P862:ABBV-383(一种BCMA×CD3双特异性T细胞定向抗体)治疗复发/难治性多发性骨髓瘤的I期首次人体单药治疗研究

Höchsmann, Christoph; Martin, Corby K; Apolzan, John W; Dorling, James L; Newton, Robert L Jr; Denstel, Kara D; Mire, Emily F; Johnson, William D; Zhang, Dachuan; Arnold, Connie L; Davis, Terry C; Fonseca, Vivian; Thethi, Tina K; Lavie, Carl J; Springgate, Benjamin; Katzmarzyk, Peter T; Weisel, Katja; D’souza, Anita; Hurd, David; Voorhees, Peter; Teipel, Raphael; Chung, Alfred; Rodriguez, Cesar; Tuchman, Sacha; Korde, Neha; Safah, Hana; Bueno, Orlando; Feng, Zhongling; Rosenberg, Tanya; Kumar Pothacamury, Rajvineeth; Ross, Jeremy; Lee, Shane; Jin, Ziyi; Talati, Chetasi; Kumar, Shaji; Vij, Ravi

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

ABBV-383(一种B细胞成熟抗原×CD3双特异性T细胞重定向抗体)在复发/难治性多发性骨髓瘤患者中的I期首次人体研究

D'Souza, Anita; Shah, Nina; Rodriguez, Cesar; Voorhees, Peter M; Weisel, Katja; Bueno, Orlando F; Pothacamury, Rajvineeth K; Freise, Kevin J; Yue, Susan; Ross, Jeremy A; Polepally, Akshanth R; Talati, Chetasi; Lee, Shane; Jin, Ziyi; Buelow, Ben; Vij, Ravi; Kumar, Shaji